Yale Cancer Center and our partner, Smilow Cancer Hospital at Yale-New Haven, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for breast center is listed below.
Breast Cancer Performance Rates
- Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with T1c N0 M0, or sate II or III ERA and/or PRA positive breast cancer.
- Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.
- Combination chemotherapy is considered or administered within 4 months of diagnosis for women under age 70 with T1c N0 M0, or stafe II or III ERA and PRA negative breast cancer.